EP 0711168 A4 19980401 - METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS
Title (en)
METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS
Title (de)
VERFAHREN ZUR BEHANDLUNG VPN APOPTOSE UND DAMIT VERBUNDENEN ZUSTAENDEN
Title (fr)
PROCEDES DE TRAITEMENT DE L'APOPTOSE ET D'ETATS ASSOCIES
Publication
Application
Priority
- US 9408268 W 19940722
- US 9678893 A 19930723
Abstract (en)
[origin: WO9503054A1] Methods are presented to prevent or delay apoptosis by administering a therapeutically effective amount of a physiologically acceptable dioxopiperazine.
IPC 1-7
IPC 8 full level
C07D 241/08 (2006.01); A61K 31/495 (2006.01); A61P 13/02 (2006.01); A61P 15/00 (2006.01); A61P 17/00 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP KR)
A61K 31/495 (2013.01 - EP KR); A61P 13/02 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); Y02A 50/30 (2017.12 - EP)
Citation (search report)
- [X] WO 9208460 A1 19920529 - WINDLESHAW ENTERPRISES LTD [GB]
- [X] TANABE ET AL.: "Inhibition of Topoisomerase II by Antitumor Agents Bis(2,6-dioxopiperazine) Derivatives", CANCER RESEARCH, vol. 51, 1991, pages 4903 - 4908, XP002046914
- [X] SEHESTED ET AL.: "ANTAGONISTIC EFFECT OF THE CARDIOPROTECTOR (+)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187) ON DNA BREAKS AND CYTOTOXICITY INDUCED BY THE TOPOISOMERASE II DIRECTED DRUGS DAUNORUBICIN AND ETOPOSIDE (VP-16)", BIOCHEMICAL PHARMACOL., vol. 46, no. 3, 1993, pages 389 - 393, XP002046915
- [X] CHACHOUA ET AL.: "Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS)", INVEST. NEW DRUGS, vol. 7, no. 4, 1989, pages 327 - 332, XP002046916
- [X] HELLMAN K.: "Effect of ICRF 159 on Immune Responses.", PROC. ROY. SOC. MED., vol. 65, no. 3, 1972, pages 264 - 265, XP002046917
- [X] DUKE ET AL.: "Immunosuppression by the Bisdioxopiperazines ICRF 154 and 159", BIOMEDICINE, vol. 18, no. 3, 1973, pages 199 - 205, XP002046918
- [X] HAUG ET AL.: "Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, razoxane and interferon.", CELL PROLIFERATION, vol. 26, no. 3, - 1993, pages 251 - 261, XP002046919
- [X] BU'LOCK ET AL.: "Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease", BRITISH HEART JOURNAL, vol. 70, no. 2, 1993, pages 185 - 188, XP002046920
- [X] HERMAN ET AL.: "Protective Effect of ICRF-187 on Doxorubicin-Induced Cardiac and Renal Toxicity in Spontaneously Hypertensive (SHR) and Normotensive (WKY) Rats", TOXICOL. APPL. PHARMACOL., vol. 92, no. 1, 1988, pages 42 - 53, XP002046921
- [X] HERMAN ET AL.: "Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.", CANCER CHEMOTHER. PHARMACOL., vol. 32, no. 6, 1993, pages 445 - 449, XP002046922
- [X] HERMANN ET AL.: "Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy", CANCER TREAT. REVIEWS, vol. 17, no. 2-3, 1990, pages 155 - 160, XP002046923
- [PX] ONISHI ET AL.: "BIS(2,6-DIOXOPIPERAXINE) DERIVATIVES, TOPOISOMERASE ii INHIBITORS WHICH DO NOT FORM A DNA CLEAVABLE COMPLEX, INDUCE THYMOCYTE APOPTOSIS", BIOCHEM. MOL. BIOL. INT., vol. 32, no. 1, 1994, pages 115 - 122, XP002046924
- See references of WO 9503054A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9503054 A1 19950202; AU 7370594 A 19950220; BR 9407145 A 19960917; CA 2167805 A1 19950202; EP 0711168 A1 19960515; EP 0711168 A4 19980401; JP H09503749 A 19970415; KR 960703597 A 19960831
DOCDB simple family (application)
US 9408268 W 19940722; AU 7370594 A 19940722; BR 9407145 A 19940722; CA 2167805 A 19940722; EP 94922680 A 19940722; JP 50532795 A 19940722; KR 19960700340 A 19960123